Psoriasis disease severity affects patient satisfaction with treatment

Dermatol Online J. 2015 Jul 15;21(7):13030/qt69h903m6.

Abstract

Background: Patients with psoriasis are often dissatisfied with available treatments, but contributing factors are not well defined.

Objective: Examine relationships between psoriasis severity, patient characteristics, and treatment satisfaction.

Methods: Patients with psoriasis were classified into mild and moderate-to-severe groups based on self-reported data. Demographics, comorbidities, symptoms, and multiple treatment satisfaction outcomes were compared between groups. Predictors of patient satisfaction with treatment were examined using linear regression models.

Results: The analyses included 773 patients (407 mild; 366 moderate-to-severe). The percentage of patients reporting satisfaction with treatment was low overall, ranging from 8.6% to 61.7% for the mild and 13.9% to 49.5% for the moderate-to-severe group. Satisfaction among biologics users was also low (≤53%; 50% of satisfaction rates <40%). Regression results consistently showed greater dissatisfaction with current treatment among moderately to severely affected patients.

Conclusion: Many psoriasis patients were dissatisfied with their treatment; moderate-to-severe patients expressed significantly less satisfaction than mild patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biological Products / therapeutic use
  • Cohort Studies
  • Cross-Sectional Studies
  • Dermatologic Agents / therapeutic use
  • Female
  • Humans
  • Linear Models
  • Logistic Models
  • Male
  • Middle Aged
  • PUVA Therapy / methods
  • Patient Satisfaction / statistics & numerical data*
  • Predictive Value of Tests
  • Psoriasis / diagnosis*
  • Psoriasis / psychology
  • Psoriasis / therapy*
  • Quality of Life*
  • Self Report*
  • Severity of Illness Index
  • Sickness Impact Profile
  • Treatment Outcome
  • United States
  • Young Adult

Substances

  • Biological Products
  • Dermatologic Agents